LI Chunzhen,ZHANG Dongfeng,LIU Ling,CUI Jieyuan,YUAN Xiaoying,LIU Fujuan,YANG Yanjun . The application of hemoperfusion in severe juvenile dermatomyositis [J]., 2014, 32(2): 144-146.
[1] Bohan A，Peter JB. Polymyositis and dermatomyositis(first of two parts) [J]. N Engl J Med，1975，292(7)：344-347. [2] Ernste FC，Crowson CS，de Padilla CL,et al. Longitudinal Peripheral Blood Lymphocyte Subsets Correlate with Decreased Disease Activity in Juvenile Dermatomyositis [J]. J Rheumatol，2013，40(7)：1200-1211. [3] 吴蔚，王胜军，李遇梅，等. 皮肌炎患者外周血CD4+Th1/Th2细胞因子及转录因子的表达 [J]. 江苏医药，2008，34（9）：867-869. [4] Oddis CV，Reed AM，Aggarwal R，et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis： a randomized，placebo-phase trial [J]. Arthritis Rheum，2013，65(2)：314-324. [5] Yokoyama T，Shimizu M，Ishikawa S，et al. Accumulation of mature B cells in the inflamed muscle tissue of a patient with anti-155/140 antibody-positive juvenile dermatomyositis [J]. Mod Rheumatol，2013，23(1)：167-171. [6] Shrestha S，Wershil B，Sarwark JF，et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells [J]. Arthritis Rheum，2010，62(9)：2813-2822. [7] Kim E，Cook-Mills J，Morgan G，et al. Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126 [J]. Arthritis Rheum，2012，64(11)：3809-3017. [8] 李澄，刘升云，冯树芳，等. 皮肌炎患者血清中TGF-β1及GM-CSF细胞因子水平的测定 [J]. 中国免疫学杂志.2003，19（7）：509-510. [9] Baechler EC，Bilgic H，Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis [J]. Arthritis Res Ther，2011，13(6)：249. [10] Niewold TB，Wu SC，Smith M，et al. Familial aggregation of autoimmune disease in juvenile dermatomyositis [J]. Pediatrics，2011，127(5)：e1239-e1246. [11] Kim NN，Lio PA，Morgan GA，et al. Double trouble： therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis [J]. Arch Dermatol，2011,147(7)：831-835. [12] Chiu YE，Co DO. Juvenile dermatomyositis： immunopathogenesis，role of myositis-specific autoantibodies，and review of rituximab use [J]. Pediatr Dermatol，2011,28(4)：357-367. [13] Bader-Meunier B，Decaluwe H，Barnerias C，et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis：results from 9 patients from the French Autoimmunity and Rituximab registry [J]. J Rheumatol，2011，38(7)：1436-1440. [14] Rosa Neto NS，Goldenstein-Schainberg C. Juvenile dermatomyositis：review and update of the pathogenesis and treatment [J]. Rev Bras Reumatol，2010，50(3)：299-312. [15] Bustos BR，Carrasco AC，Toledo RC. Plasmapheresis for macrophage activation syndrome and multiorgan failure as first presentation of juvenile dermatomyositis [J]. An Pediatr (Barc)，2012,77(1)：47-50. [16] 李丰，曾华松，儿童皮肌炎的诊断与治疗[J].实用儿科临床杂志，2012，27（21）：1694-1696.
